SPDL1 and Miyoshi myopathy: In contrast with these previous trials, in this study sPD-L1 levels were below the limit of quantitation following durvalumab treatment, indicating complete target coverage, even in the presence of elevated screening levels of sPD-L1 in patients with MM.